1. Addressing Cognitive and Psychiatric Effects of Antiepileptic Drugs

2. Program Goals

3. Lifetime Prevalence of Psychiatric Comorbidities in Epilepsy

4. Mechanisms Operant in the Development of Psychiatric Iatrogenic Symptomatology

5. AEDs With Psychotropic Properties

7. Pathogenic Mechanisms for AED-Induced Depression

8. Psychiatric Adverse Effects in Patients With Epilepsy Treated With Topiramate

10. Effect of Co-occurrence of Depression With Other Histories During Rapid Topiramate Titration

11. Discontinuation of Levetiracetam Related to Psychiatric Adverse Effects

12. Dose of Levetiracetam and Psychiatric Adverse Effects

13. AEDs and Suicidality FDA Conclusions From Meta-Analysis

14. FDA Meta-Analysis Suicidal Behavior or Ideation Stratified by AED

15. FDA Meta-Analysis Methodological Concerns

16. Antiepileptic Drugs and Suicidality Expert Consensus Statement

17. Risk Factors for Suicidality in Epilepsy

18. Can Iatrogenic Psychiatric Symptoms/Effects Be Prevented?

19. Iatrogenic Cognitive Effects of AEDs Basic Concepts

20. Cognitive Abilities Affected by AEDs

21. First-Generation AEDs Cognitive Effects in Healthy Adults

22. Second-Generation AEDs Cognitive Effects in Healthy Adults

23. Newer AEDs vs Other AEDs In Healthy Volunteers

24. Delayed Recall in Healthy Volunteers

25. Third-Generation AEDs Iatrogenic Cognitive Effects

26. AEDs With Specific Iatrogenic Cognitive Deficits

27. Prevention of Iatrogenic Cognitive Adverse Effects

28. Summary

29. Abbreviations

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)